What is an AMAS test?

AMAS test is a blood test developed by Dr. Samual Bogosh MD, PhD and his wife Dr. Eleanore Bogosh MD.  Dr. Bogosh is a Harvard-trained neurochemist who researched the anti-malignin antibody. 

The AMAS test is patented and FDA approved.  

Anti-Malignin Antibody (AMA) is the antibody to Malignin, a 10,000 Dalton polypeptide which has been found to be present in most malignant cells regardless of cell type or location.  The AMASŪ test measures a well-defined antibody whose serum levels rise early in the course of the disease.  On the other hand, since antibody failure often occurs late in malignancy, elevated antibody is then no longer available as evidence of the presence of antigen and therefore, late in the disease, the AMASŪ test cannot be used as a diagnostic aid, but may be useful for monitoring.

How accurate is this AMAS test?  

In studies of more than 8,000 patients, the AMASŪ Test was found to be 95% accurate and unique for its diverse use as a diagnostic tool regarding all non-terminal cancers.

This test indicates with great accuracy (99% specificity and 95% sensitivity) if there is cancer active anywhere within your body.  This test does not indicate where cancer may be located so other diagnostic tests must be used for this purpose.  

As with any lab test, the AMAS test must be combined with a thorough history, examination, and other clinical and laboratory testing by a Doctor experienced with Natural Medicine and the AMAS test for effective interpretation.

Is the AMAS test scientifically researched?

Yes.  At least a dozen major hospitals in the United States, 3 in Great Britain, and 3 independent laboratories have participated in the large research studies.  The largest study involved 4200 tests done by 3 separate independent laboratories.  This test has been in use in the US for more than 10 years. 

Unfortunately, many doctors trained in only crisis care and disease care, who have only drugs as treatment tools, have not been trained to use the AMAS test. Medline, an online medical research database, has more information on the research behind this test.   

What cancers do the AMAS test help to detect?

In an 8,090 patient case study, AMASŪ concentration elevation proved to be a universal immune response in breast, prostate, lung, colon and all other common forms of human cancer.  Other cancers that have been investigated have been: brain, melanomas, lymphomas, leukemias, and colorectal malignancies. Also included are smaller numbers of malignancies of the larynx, uterus, cervix, ovary, anus, stomach, esophagus, prostate, bladder, urethra, kidney, testis, thyroid, skin and fibrosarcoma, leimyosarcoma, osteogenic sarcoma, rhabdomysarcoma, mesothelioma, liposarcoma and hemangioblastoma.

Is the AMAS test useful for early cancer detection?

Yes.  In some cases, the AMASŪ test has been positive (elevated) early, i.e. 1 to 19 months before clinical detection.  When a clinical situation involves signs or symptoms suggesting a disorder which may or may not be malignant, and current methods of detection including physical examination, x-rays, CT scans, mammograms, PAP smears and biopsies provide borderline or inconclusive, AMAS test results may help the physician in the diagnostic process.

Cancer survival and the AMAS test.

Another use of the AMASŪ test is in indicating disease progression and prognosis. Thus in known cancer patients, when the immune response is good, as evidenced by high antibody levels, the prognosis is good; and when the antibody level falls, the prognosis is poor.

Anti-malignin antibody is the first general cancer antibody found to relate to patient survival. The test therefore may be useful as an adjunct to standard (sometimes less accurate) staging information such as the spread of malignancy beyond the capsule of the primary organ and the presence of metastases in lymph nodes, or general symptoms such as anemia, weight loss and fatigue.

Where can I get this test?  

We have this test available at NEWS.  Most traditional medical clinics are usually not aware of this test or downplay the test. This happens because traditional medical school training does not include tests like the AMAS test or natural medicine immune strengthening and repairing approaches. 

In summary:

Anti-Malignin Antibody is elevated in 93-100% of cases in which active nonterminal malignancy is the diagnosis;  AMA is normal in 96% of cancer patients who no longer have evidence of disease.

1. The low false-positive and false-negative rates (<1 % on repeat determinations of 24-hour sera) have permitted successful screening in selected high-risk populations and in the preclinical detection of cancer, but the efficacy of screening in larger normal populations has yet to be determined.
2. A normal AMA level can occur in non-cancer, in terminal cancer, and in successfully treated cancer in which there is no further evidence of disease; clinical status must be used to distinguish these states.
3. As in all clinical laboratory tests, the AMASŪ test is not by itself diagnostic of the presence or absence of disease, and its results can only be assessed as an aid to diagnosis, detection or monitoring of disease in relation to the history, medical signs and symptoms and the overall condition of the patient.

Other websites of interest about the AMASŪ test are: